Background. The demand for human hematopoietic stem and progenitor cells (HSPCs) for transplantation is increasing. Thus, effective alternative sources of HSPCs are required. Consequently, we sought to expand the accessibility of hematopoietic cells for clinical purposes by the investigation of hematopoietic reconstitution after transplantation of human HSPCs harvested from the bone marrow (BM) of heparinized deceased organ donors (HDODs).
Methods. For multipart research comparison, human BM HDODs-, healthy donor-derived, umbilical cord blood nuclear cells, or CD34+ cells were transplanted into sublethally irradiated NOD/SCID mice. Twenty-eight days after transplantation nuclear cells were isolated from the murine BM, spleen, and peripheral blood and were used to quantitatively detect human CD45 antigen by quantitative real-time reverse transcriptase–polymerase chain reaction and flow cytometry. The clonogenic growth of human colony-forming units was also investigated.
Results. We found that umbilical cord blood-derived HSPCs showed the greatest transplantation potential in our in vivo model. Interestingly, the transplantation potential of HSPCs collected from the BM of HDODs was of the same quality as cells obtained from healthy BM donors.
Conclusion. Based on these results, we conclude that HDODs are a strongly underappreciated source of HSPCs that are ready to use for clinical purposes.
1Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.
2Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland.
3Department of Nephrology, Transplantology, and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.
4Department of General and Transplant Surgery, Pomeranian Medical University, Szczecin, Poland.
This work was supported by the National Science Center grant No. 6133/B/P01/2011/40 (B.M.) and by the European Union within the European Social Fund, “Investment in knowledge as a driving force for development of innovation in the region”—implemented within the framework of Subaction 8.2.2 Regional Strategies of Innovation SOP HRD 2007–2013 (B.B.).
The authors declare no conflicts of interest.
Address correspondence to: Bogusław Machaliński, M.D., Ph.D., D.Sc., Department of General Pathology, Pomeranian Medical University, Al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland. E-mail: email@example.com
B.B. performed research, analyzed data, and wrote the manuscript; M.P.K., M.K., K.G., and E.P. performed research; K.S. analyzed data; K.P., J.P.P., M.W., and M.O. collected data; B.M. designed research, reviewed the manuscript, and study protocol.
Received 1 August 2011. Revision requested 2 September 2011.
Accepted 21 October 2011.